Safety and Efficacy of Intrapulmonary Percussive Ventilation in Preterm Infants

Launched by AUGUSTA UNIVERSITY · Jan 26, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment called Intrapulmonary Percussive Ventilation (IPV) for premature infants who are struggling with a condition known as Respiratory Distress Syndrome. The goal is to see if IPV can help these tiny patients breathe better and clear mucus from their lungs while ensuring it's safe for them to use. IPV has shown promise in helping children with similar breathing issues, and researchers want to find out how effective it is for infants born before 32 weeks of pregnancy.

To participate in this study, infants need to be born prematurely (before 32 weeks) and weigh less than 1500 grams at birth. They should also need help with breathing through a ventilator within the first two weeks of life. However, infants with certain conditions, like specific genetic disorders or lung issues, won't be eligible to join. If a baby qualifies and participates, the study will monitor how well IPV works for them and any potential effects it may have. This trial is not yet recruiting, so families interested in this treatment will need to wait for further announcements.

Gender

ALL

Eligibility criteria

• • INCLUSION CRITERIA
• • Premature infants born before 32 weeks of gestation with birth weight less than 1500 grams.
• • Infants requiring positive pressure ventilation by 14 days of life. EXCLUSION CRITERIA
• • Infants with known or suspected chromosomal anomalies (Trisomy 13, 18, 21)
• • Infants with Congenital Diaphragmatic Hernia
• • Presence of air leak syndrome (pneumothorax, pneumomediastinum)
• • Previous diagnosis of air leak syndrome.